Compare TOL & PEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TOL | PEN |
|---|---|---|
| Founded | 1967 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.1B | 12.6B |
| IPO Year | 1994 | 2015 |
| Metric | TOL | PEN |
|---|---|---|
| Price | $134.30 | $318.87 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 17 | 16 |
| Target Price | $164.44 | ★ $360.14 |
| AVG Volume (30 Days) | ★ 656.9K | 233.3K |
| Earning Date | 05-19-2026 | 05-12-2026 |
| Dividend Yield | ★ 0.72% | N/A |
| EPS Growth | N/A | ★ 1155.56 |
| EPS | ★ 7.87 | 1.70 |
| Revenue | ★ $7,143,258,000.00 | $1,403,665,000.00 |
| Revenue This Year | N/A | $14.34 |
| Revenue Next Year | $6.01 | $13.71 |
| P/E Ratio | ★ $17.13 | $187.49 |
| Revenue Growth | N/A | ★ 17.50 |
| 52 Week Low | $123.15 | $221.26 |
| 52 Week High | $168.36 | $362.41 |
| Indicator | TOL | PEN |
|---|---|---|
| Relative Strength Index (RSI) | 36.42 | 43.22 |
| Support Level | $130.33 | $315.31 |
| Resistance Level | $153.78 | $320.45 |
| Average True Range (ATR) | 3.25 | 1.88 |
| MACD | -0.67 | -0.40 |
| Stochastic Oscillator | 22.35 | 24.68 |
Toll Brothers is the leading luxury homebuilder in the United States with an average sale price well above public competitors'. The company operates in over 60 markets across 24 states and caters to move-up, active-adult, and second-homebuyers. Toll Brothers consistently ranks as a top 10 builder within the US according to total home closings. Traditional homebuilding operations represent most of the company's revenue. Toll Brothers also builds luxury for-sale and for-rent properties in urban centers across the US It has its headquarters in Horsham, Pennsylvania.
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.